I
Innovacell
Biotech & Life Sciences · Tokyo, Japan · Founded 2000
Autologous cell therapies for treating incontinence MoreLess
Innovacell is a clinical-stage biotechnology company developing and commercializing autologous cell therapies for fecal and urinary incontinence. The company's core technology involves extracting a patient's own skeletal muscle cells, multiplying them in a specialized facility, and then reinjecting them into the weakened sphincter muscle to regenerate tissue and restore function. This approach aims to provide a permanent cure through a minimally invasive procedure.
The company's history began in 2000, when Innovacell Biotechnologie GmbH was founded in Innsbruck, Austria, as a spin-off from the Medical University of Innsbruck by Ekkehart Steinhuber and Rainer Marksteiner. The firm changed its corporate structure to an AG (a public limited company) in 2008 and focused on advancing its cell therapies through clinical trials. A significant restructuring occurred in 2021, when Innovacell K.K. was established in Tokyo, Japan, becoming the parent company to the Austrian entity (now Innovacell GmbH). This move was driven by Japan's favorable regulatory environment for regenerative medicine and its ambition to become a global leader in the field. The company went public on the Tokyo Stock Exchange in February 2026.
Innovacell's business model is described as a "Regenerative Medicine Product Global Aggregation Model," which involves identifying promising regenerative medicine candidates worldwide and leveraging its expertise to advance them through development and commercialization. The company's lead product candidate, ICEF15, is an autologous skeletal myoblast cell therapy for urge fecal incontinence, which is in multi-regional Phase III clinical trials in Europe and Japan. Other pipeline products include ICES13 for stress urinary incontinence (completed Phase II) and ICEF16 for passive fecal incontinence (preclinical). Innovacell has developed proprietary ultrasound-guided instruments for the precise injection of the cultivated cells. The company operates one of Europe's largest GMP-certified manufacturing facilities for cell cultivation in Innsbruck.
Keywords: autologous cell therapy, regenerative medicine, fecal incontinence, urinary incontinence, tissue engineering, skeletal muscle cells, sphincter muscle regeneration, clinical-stage biotechnology, ICEF15, ICES13, cell-based therapeutics, minimally invasive treatment, GMP manufacturing, myoblasts, urogenital diseases, gastroenterology, personalized medicine, sphincter regeneration, biotechnology, clinical trials
Company overview
Innovacell company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2000
- Headquarters
- Tokyo, Japan
- Employees
- 27
- Open positions
- None listed
- Dealroom signal
- 86.8
Valuation & funding
Innovacell funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| IPOOther financing | Feb 2026 | $91M | — | Undisclosed | ↗ |
| SERIES DOther financing | Nov 2025 | $56M | $224M | Undisclosed | — |
| SERIES DOther financing | Aug 2025 | $50M | $200M | M&G · Happiness Capital · Aska Pharmaceutical · SBI Investment | — |
| SERIES COther financing | Jul 2022 | $20M | $80M | Medipal · SBI Investment · Fiducia · HiJoJo Partners | — |
| DEBTDebt | Mar 2022 | $17M | — | European Investment Bank | ↗ |
| SERIES BOther financing | Jan 2019 | ID Pharma · Ci:z Investment | — | ||
| LATE VCOther financing | Feb 2012 | Horizonte Venture Management · Buschier · Alpine Equity Management · Fides Capital Management | — | ||
| SPINOUTOther financing | Jan 2000 | Medical University of Innsbruck | — |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $7.7M | — | −$25M | -321.5% |
| 2025 | $0 | — | −$15M | — |
| 2024 | $0 | — | −$13M | — |
| 2023 | $0 | — | −$12M | — |
Growth signals
Innovacell website traffic
Latest recorded traffic for Innovacell is 970 monthly website visits, down 96% over the last three months. Innovacell's team grew 0% over the past year.
Comparisons
Innovacell compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Innovacell's talent
Source: Dealroom Talent Intelligence.
Investors
15 investors on Innovacell's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where Innovacell has talent and traffic
team presence
In the news
Latest news about Innovacell
Recent press, funding announcements, and product moves mentioning Innovacell — open to read from the original sources.
Market sentiment
What the market is saying about Innovacell
An AI-synthesized read of the highest-engagement posts about Innovacell on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Innovacell’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.